Truscreen Completes Capital Raising

9 July 2019

NZX Announcement

TRUSCREEN COMPLETES CAPITAL RAISING
Truscreen Limited (Truscreen or Company) (NZX: TRU) is pleased to advise that it has
received firm commitments for the capital raising announced on 2 July 2019, raising
NZ$1,000,000, before costs.
The Company will issue 9,433,962 new ordinary shares at a price of 10.6 cents per share,
an 18.5% discount to the last trading price on 1 July 2019. The New Shares will also be
entitled to a free attaching option, exercisable at 13 cents per share with expiry date two
years from date of issue. This raising includes placement shares (and attaching options) to
be subscribed for by the Chairman in the amount of NZ$106,000, which is subject to
shareholder approval at the Annual Meeting of Shareholders to be held on 27 August 2019.
The funds will be used for working capital as the business grows to meet the expanding
demand from those countries where the Company has established business, and for
developing new markets identified for the Company’s product.

For more information visit www.TruScreen.com or contact:

TruScreen
Martin Dillon
CEO
martindillon@truscreen.com

TruScreen
Guy Robertson
CFO
guyrobertson@truscreen.com
Investors
Investor Relations
Phone: +61 2 9237 2801
TruScreen@we-buchan.com

About TruScreen:
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen-
ultra-video/
TruScreen is a Cervical Cancer Screening Device
which offers the latest technology in cervical
screening, providing real-time, accurate detection
of pre-cancerous and cancerous cervical cells to
help improve the health and well-being of women
around the world. TruScreen’s real-time cervical cancer
technology utilises a digital wand which is placed on the surface
of the cervix to measure electrical and optical signals from the
surrounding tissues. A sophisticated proprietary algorithm
framework is utilised to detect pre-cancerous change, or cervical
intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.
TruScreen offers an alternative approach to cervical screening, resolving many of the
ongoing issues with Pap tests including failed samples, poor patient follow up, patient
discomfort and the need for supporting laboratory infrastructures. As such, TruScreen
target market is developing countries where no large scale cervical cancer screening
programs and infrastructure are in place, such as; China, Mexico, Africa, Russia and India.
TruScreen’s cervical cancer screening device is EC certified for use throughout Europe and
CFDA approved for sale in China. Truscreen gained recognition from Global NGO’s WHO and
Unitaid in a joint Cervical Cancer Technology Landscape released at the 72
nd
World Health
Assembly.
For more information, visit our website at www.truscreen.com